{"podcast":{"title":"START","slug":"start-7171926","podcast_index_feed_id":7171926,"rss_url":"https://feeds.transistor.fm/startup-growth-podcast","website_url":"https://www.tryfondo.com/","image_url":"https://img.transistorcdn.com/_piHi4M4ohHZpDkziNHWWksxxbatgWrUdPwb5S4zcyo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80NzVj/MDEzNjkxNjU1N2Uy/NDFhMDQ3M2ZhNWI3/NWY0MS5wbmc.jpg","author":"Fondo","episode_count":97,"summary":"Fondo is an all-in-one accounting platform for startups. Get your books closed, taxes filed, and cash back from the IRS.","last_synced_at":"2026-08-01T06:21:07.655766+00:00","page_url":"https://stenobird.com/podcast/start-7171926"},"episode":{"title":"START pod: Jeff Liu, CEO & Co-Founder, FinalDose \"Programmable DNA drug destroying all cancers, unlocking 80% of targets\"","slug":"start-pod-jeff-liu-ceo-co-founder-finaldose-programmable-dna-drug-destroying-all-cancers-unlocking-80-of-targets","published_at":"2026-05-26T22:02:26+00:00","page_url":"https://stenobird.com/podcast/start-7171926/start-pod-jeff-liu-ceo-co-founder-finaldose-programmable-dna-drug-destroying-all-cancers-unlocking-80-of-targets","show_page_url":"https://stenobird.com/podcast/start-7171926","url":"https://share.transistor.fm/s/77daffff","audio_url":"https://media.transistor.fm/77daffff/fe22418c.mp3","summary":"Most cancer drugs target proteins FinalDose thinks the real opportunity is one layer deeper: DNA Jeff Liu and his team are building a programmable drug platform that uses genetic mutations to identify and selectively destroy cancer cells Cells without those mutations are not targeted Instead of creating a completely new drug for every cancer type, the platform is designed as a reusable system with different genetic instructions One chassis. Different disease targets. The broader bet: DNA is more deterministic than proteins, which could unlock therapeutic approaches traditional drugs struggle to reach Search. Destroy. \"A programmable cell elimination platform.\" 🎙️ Jeff Liu, Cofounder & CEO of FinalDose on START 00:11 Why proteins may be the wrong layer for cancer treatment 01:14 Using DNA mutations as programmable kill signatures 03:20 Building a reusable therapeutic platform instead of one-off drugs 05:00 Why hard biotech problems require interdisciplinary teams 06:00 Getting into YC after a 4 a.m. interview in Japan 08:00 Sam Altman’s $2M AI token offer — and why FinalDose passed 10:08 How AI-native biotech is accelerating programmable medicine 12:00 Why the future of medicine may look more like engineering 13:05 The regulatory bottleneck for programmable therapeutics Learn more at finaldose.ai","meta_description":"Most cancer drugs target proteins FinalDose thinks the real opportunity is one layer deeper: DNA Jeff Liu and his team are building a programmable drug pl…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1075,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/start-7171926/episodes/start-pod-jeff-liu-ceo-co-founder-finaldose-programmable-dna-drug-destroying-all-cancers-unlocking-80-of-targets/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/start-7171926/start-pod-jeff-liu-ceo-co-founder-finaldose-programmable-dna-drug-destroying-all-cancers-unlocking-80-of-targets.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}